These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 7623914)
1. Adjuvant chemotherapy in breast cancer. Del Mastro L; Costantini M; Bianco AR N Engl J Med; 1995 Aug; 333(9):596; author reply 597. PubMed ID: 7623914 [No Abstract] [Full Text] [Related]
2. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K; Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922 [TBL] [Abstract][Full Text] [Related]
3. [Quality outcome of adjuvant CMF therapy in patients with breast cancer]. Kleeberg UR Strahlenther Onkol; 2000 Jun; 176(6):290-1. PubMed ID: 10897257 [No Abstract] [Full Text] [Related]
4. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS; J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194 [TBL] [Abstract][Full Text] [Related]
5. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes]. Nagykálnai T Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352 [TBL] [Abstract][Full Text] [Related]
6. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M; Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials. Albain KS J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631 [No Abstract] [Full Text] [Related]
8. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Kumpulainen EJ; Hirvikoski PP; Johansson RT Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780 [TBL] [Abstract][Full Text] [Related]
9. [The adjuvant chemotherapy of breast cancer]. Semiglazov VF; Golubeva OM; Bavli IaL; Ivanova OA; Topuzov EE Vopr Onkol; 1992; 38(10):1187-94. PubMed ID: 1343144 [TBL] [Abstract][Full Text] [Related]
10. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Ejlertsen B; Mouridsen HT; Jensen MB Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334 [TBL] [Abstract][Full Text] [Related]
12. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428 [TBL] [Abstract][Full Text] [Related]
13. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN; N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747 [TBL] [Abstract][Full Text] [Related]
14. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027 [TBL] [Abstract][Full Text] [Related]
15. Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer. Bonadonna G; Valagussa P; Veronesi U J Clin Oncol; 2008 Jan; 26(3):342-4. PubMed ID: 18202404 [No Abstract] [Full Text] [Related]
16. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS; Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830 [TBL] [Abstract][Full Text] [Related]
17. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341 [TBL] [Abstract][Full Text] [Related]
18. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293 [TBL] [Abstract][Full Text] [Related]
19. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer. Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926 [TBL] [Abstract][Full Text] [Related]
20. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y; Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]